Last reviewed · How we verify
NCT06140797: PRACTICE
Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery
NA trial testing Multimodal prehabilitation combined with perioperative ERAS care（PREERAS） in Spine Degeneration in 164 participants. Completed in 10 September 2025.
10 September 2025
Quick facts
| Lead sponsor | Xuanwu Hospital, Beijing |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 164 |
| Start date | 15 April 2024 |
| Primary completion | 10 September 2025 |
| Estimated completion | 10 September 2025 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Multimodal prehabilitation combined with perioperative ERAS care（PREERAS）
Conditions studied
- Spine Degeneration — all drugs for Spine Degeneration →
- Spine Fusion — all drugs for Spine Fusion →
- Frailty Syndrome — all drugs for Frailty Syndrome →
Sponsor
Xuanwu Hospital, Beijing
Who can join
75 and older, any sex, with Spine Degeneration or Spine Fusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With the extended life expectancy of the Chinese population and improvements in surgery and anesthesia techniques, the number of aged patients undergoing surgery has been increasing annually. However, safety, effectiveness, and quality of life of aged patients undergoing surgery are facing major challenges. This prospective, multi-center, randomized, controlled study aims to construct a prehabilitation combined with enhanced recovery after surgery program which includes pre-operative risk assessment and targeted intervention.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Multimodal prehabilitation combined with perioperative enhanced recovery after surgery care for older patients undergoing spinal fusion surgery in China: protocol for a multicentre randomised controlled trial (PRACTICE trial).
Wang SK, Wang P, Wang W, Lu S. · · 2024 · cited 5× · PMID 39663170 · DOI 10.1136/bmjopen-2024-088339
Verify or expand the search:
- PubMed search for NCT06140797
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Spine Degeneration
Currently open trials in the same condition.
- NCT07026552 — Proteomic and Histological Analysis of Ligamentum Flavum in Lumbar Stenosis · recruiting
- NCT05817747 — Strategic Use of Big Data in Spine Surgery - Testing Digital Prediction of Outcome in Clinical Praxis · NA · recruiting
Other Xuanwu Hospital, Beijing trials
Trials by the same sponsor.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
- NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
- NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
- NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06140797 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
- Last refreshed: 23 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06140797.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing